|Filed Under:||Medical / Pharmaceutical|
|Posts on Regator:||3625|
|Posts / Week:||10.3|
|Archived Since:||November 10, 2008|
A former Teva employee claims she was fired for helping U.S. officials with their investigation into FCPA violations.
Good morning, everyone, and how are you today? The heat continues to rise higher here on the Pharmalot campus, where we are hoping for storm clouds to wash away the humidity that has so far characterized the past few days. One can dream,...Show More Summary
Yet another California county plans to ask the pharmaceutical industry to fund a drug take-back program.
New research finds some serious risks are not disclosed on consent forms given to trial participants for studies involving approved drugs.
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Show More Summary
Former Merck vaccine head Adel Mahmoud explains the reasoning for creating a global vaccine development fund.
Some Mylan shareholders claim in a lawsuit that a tax inversion the drug maker pursued to thwart hostile takeovers was predicated on a “sham” and that Mylan executives breached their fiduciary duty.
Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot campus than from our ritual cup of stimulation. But this is to be expected at this time of year, yes? In any event, there is work to be done, so as always, we have assembled a few items of interest for you. Show More Summary
The European Union has accepted a recommendation to suspend hundreds of drugs that were authorized for use based on what regulators called “flawed” studies conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India.
U.K. doctors and public health officials may be required to report any financial ties to drug makers under plans that are being considered by U.K. government officials.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because yet another busy few days await. After all, given the crush of recent developments, one could hardly say we are in the midst of summer doldrums, yes? So time to get on with it. Show More Summary
A survey finds cardiologists are excited by a pair of forthcoming cholesterol-lowering meds that are expected to be effective, but expensive.
And so, yet another working week will soon draw to a close. You knew this would happen, yes? As you know, this is our treasured signal to daydream about weekend plans. As is often the case, we have a rather modest agenda. We hope to catch up on paperwork and reading, indulge the short people and take a nap or three. Show More Summary
A new paper argues that the federal government could save between $15.2 billion and $16 billion annually if it negotiated with drug makers for Medicare Part D medicines and obtained the same prices that are paid by Medicaid or the Veterans Benefits Administration.
Good morning, everyone, and how are you today? We are just fine, thank you. Our spirits are lifted higher than usual today thanks to a sparkling sun and cool breezes enveloping the quieter-than-usual Pharmalot campus. This makes for a fine day to catch up on our to-do list - we hope - and forage for interesting items. Show More Summary
A group of 85 asset managers and pension funds is teaming with a U.K. non-profit campaign to pressure drug makers to disclose clinical trial data.
After months of anticipation, Biogen this morning released early-stage study data for its experimental Alzheimer’s drug and the results were mixed - as were analyst reactions.
The FDA plans to run a pair of studies to determine the extent to which consumers view claims about a drug being the number one medicine prescribed by physicians as positie nformation or as a substitute for effectiveness data.
Hello, everyone, and how are you today? A bright shiny sun and cool breezes are enveloping the Pharmalot campus, a decidedly welcome greeting from the steamy heat of the past few days. This calls for celebration. So please join us as we reach for the mandatory cup of stimulation. Show More Summary
In a decision with significant implications for health care costs, a federal appeals court ruled that Sandoz can begin selling the first biosimilar in the U.S. on Sept. 2.